This notion is supported by the combination of BRAF and MEK inhibition, which boosts the expansion of tumor-specific T cells and the abundance of TCR repertoire, which is due to the induction of TCF7 and T-bet [23,24]. The gene discussed is BRAF; the disease is neoplasm.